MétaCan
Menu
Back to cohort
Record W2100860810 · doi:10.1200/jco.2012.47.8313

Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

2013· article· en· W2100860810 on OpenAlexafffund
Kelly‐Anne Phillips, Roger L. Milne, Matti A. Rookus, Mary B. Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F. Easton, Michael Friedländer, Saundra S. Buys, Nadine Andrieu, Catherine Noguès, Dominique Stoppa-Lyonnet, Valérie Bonadona, Pascal Pujol, Sue Anne McLachlan, Esther M. John, Maartje J. Hooning, Caroline Seynaeve, Rob A.�E.�M. Tollenaar, David E. Goldgar, Mary Beth Terry, Trinidad Caldés, Prue C. Weideman, Irene L. Andrulis, Christian F. Singer, Kate Birch, Jacques Simard, Melissa C. Southey, Håkan Olsson, Anna Jakubowska, Edith Olah, Anne‐Marie Gerdes, Lenka Foretová, John L. Hopper

Bibliographic record

VenueJournal of Clinical Oncology · 2013
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBRCA gene mutations in cancer
Canadian institutionsUniversité LavalSte. Anne's Hospital
FundersNational Cancer InstituteEuropean Regional Development FundInstituto de Salud Carlos IIICanadian Institutes of Health ResearchNational Institutes of HealthMedical Research CouncilMinistero dello Sviluppo EconomicoNederlandse Organisatie voor Wetenschappelijk OnderzoekFondation de FranceMinistère du Développement Économique, de l’Innovation et de l’ExportationNational Institute for Health and Care ResearchCancer AustraliaNational Health and Medical Research CouncilGeorgetown UniversityCancer Research UKUniversity of MelbourneCanadian Breast Cancer Research AllianceCancer Care OntarioRoyal Marsden NHS Foundation TrustHuntsman Cancer InstituteNational Breast Cancer Foundation
KeywordsMedicineOncologyBreast cancerTamoxifenInternal medicineCancerGynecologyBRCA mutationMutationGeneticsGene

Abstract

fetched live from OpenAlex

PURPOSE: To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. METHODS: Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. RESULTS: Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation. The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for 56% of cases). CONCLUSION: This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased statistical power for future prospective analyses.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.503
Threshold uncertainty score0.315

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.382
Teacher spread0.356 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations170
Published2013
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicBRCA gene mutations in cancerFrench-language works237,207